Regular paperDopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities
References (16)
- et al.
Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA
Brain Res.
(1991) - et al.
Neurophysiological evidence that D1 receptor blockade attenuates postsynaptic but not autoreceptor-mediated effects of dopamine agonists
Eur. J. Pharmacol.
(1986) - et al.
Neuronal localization and modulation of the D2 receptor mRNA in brain of normal mice and mice lesioned with 6-hydroxydopamine
Neuropharmacology
(1991) - et al.
[3H]7-OH-DPAT is capable of labeling dopamine D2 as well as D3 receptors
Eur. J. Pharmacol.
(1995) - et al.
Evidence that striatal synthesis-inhibiting autoreceptors are dopamine D3 receptors
Eur. J. Pharmacol.
(1993) - et al.
SCH 23390, a selective dopamine D1 antagonist, activates dopamine neurons but fails to prevent their inhibition by apomorphine
Eur. J. Pharmacol.
(1985) Sensitivity of compacta neurones in the rat substantia nigra slice to dopamine agonists
Eur. J. Pharmacol.
(1983)- et al.
Cloning and expression of a rat D2 dopamine receptor cDNA
Nature
(1988)
Cited by (81)
Development of MCM-41 mesoporous silica nanoparticles as a platform for pramipexole delivery
2019, Journal of Drug Delivery Science and TechnologyCitation Excerpt :Neurodegenerative diseases, such as Parkinson's disease (PD) are great challenge from diagnostic and therapeutic point of view, thus alternatives and improvements to the current therapies are demanding. Pramipexole (2-amino-4,5,6,7-tetrahydro-6-propylamino-benzethiazole-dihydrochloride) is a third-generation full intrinsic dopamine receptor agonist with a nonergot structure [1]. It has been successfully used for the symptomatic treatment of early and advanced Parkinson's disease (PD), either alone or in combination with levodopa [2,3].
An endogenous dopaminergic tone acting on dopamine D <inf>3</inf> receptors may be involved in diurnal changes of tuberoinfundibular dopaminergic neuron activity and prolactin secretion in estrogen-primed ovariectomized rats
2012, Brain Research BulletinCitation Excerpt :Both synthesis and release of DA, and membrane excitability are decreased by activation of autoreceptors [31]. In addition to D2 receptors, D3 receptors have also been shown playing a role as autoreceptors [12,13,16,37]. On the other hand, the identity of autoreceptors in hypothalamic TIDA neurons (A12) has been controversial as mentioned in the Introduction.
Toxicity assessment of pramipexole in juvenile rhesus monkeys
2010, ToxicologyCitation Excerpt :Pramipexole (PPX) is a non-ergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine (DA) receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes (Kreiss et al., 1995; Mierau et al., 1995).
Dopaminergic control of food choice: Contrasting effects of SKF 38393 and quinpirole on high-palatability food preference in the rat
2006, NeuropharmacologyCitation Excerpt :These data are consistent with neurochemical findings which identify a connection between ingestion of high-palatability foods, including sucrose solutions, and enhanced levels of extracellular dopamine in the nucleus accumbens (Hajnal and Norgren, 2001; Hajnal et al., 2004; Martel and Fantino, 1996a,b). Quinpirole, like other dopamine D2/D3 receptor agonists, inhibits cell firing in the substantia nigra (Kreiss et al., 1995), and inhibits dopamine release at dopaminergic terminals (Kennedy et al., 1992) while also regulating the activity of the dopamine transporter (Zapata and Shippenberg, 2002). These drugs reduce dopamine levels in the shell and core compartments of the nucleus accumbens in freely moving rats (Shilliam and Heidbreder, 2003).
Regulation of dense core vesicle release from PC12 cells by interaction between the D2 dopamine receptor and calcium-dependent activator protein for secretion (CAPS)
2005, Biochemical PharmacologyCitation Excerpt :It will clearly be of interest to determine whether the CAPS/D2 interaction has a similar effect on dopamine secretion in neurons. A further issue that should be raised in this context is that D3 receptors have also been localized to presynaptic terminals where they are also believed to function as inhibitory autoreceptors [34,35]. Our protein interaction screens and coimmunoprecipitation experiments failed to uncover an interaction between CAPS and D3 receptors.
- 1
Current address: Pharmacology Unit, Dept. Physiology & Pharmacology, School of Medicine, University of Cantabria, Cardena Herrera Oria St., 39011 Santander, Cantabria, Spain.